adverse events

With updated COVID-19 boosters set to launch in the near future and COVID-related hospitalizations on the rise again, scrutiny is on the rise of emerging variants and the benefit-safety profile of COVID-19 vaccines. We performed a retrospective analysis of data from the Vaccine Adverse Event Reporting System (VAERS), focusing on the period covering the launch…

While numerous types of technology have a rightful place in life sciences to cut down on errors, decrease costs and boost efficiency, the adverse event intake and collection process remains primarily manual. It’s common for organizations to use software to support adverse event intake, but end-user intervention is often necessary to collect, input and share…

In the U.S., more than 125 million people have been fully vaccinated against COVID-19. While most vaccine recipients tend to have relatively minor and fleeting adverse events from the shots, many people continue to worry about side effects. According to a recent survey from the physician social network Sermo found that 72% of physicians reported…

There have multiple surges in malpractice claims following each wave of COVID-19 infections. According to Victor Bornstein, CEO of Justpoint (New York City), the vast majority of those claims have targeted medical malpractice, an AI company specializing in malpractice. “The healthcare system was under a lot of stress, and more mistakes tend to happen,” Borstein…

Now that it has been nearly four months since the FDA authorized the first COVID-19 vaccine, a considerable amount of safety information is available about the Pfizer-BioNTech vaccine. CDC recently released a summary of adverse event data related to the Pfizer-BioNTech vaccine based on more than 5,000 entries to the Vaccine Adverse Event Reporting System collected…

Patients with dermal fillers have a small potential risk of developing facial swelling after obtaining mRNA vaccines. To date, the FDA has noted the problem in three clinical trial recipients of the COVID-19 vaccine from Moderna (NSDQ:MRNA). The agency hasn’t observed facial swelling in the Phase 3 clinical trial for the COVID-19 vaccine from Pfizer…

Pfizer (NYSE:PFE) and its partner BioNTech (NSDQ:BNTX) have announced that their coronavirus vaccine was 95% effective, putting it in line with the preliminary results from rival Moderna (NSDQ:MRNA). Pfizer’s BNT162b2 vaccine candidate appears to have an advantage over Moderna’s mRNA-1273 vaccine in terms of its low adverse event rate. Out of a randomized pool of at least 8,000…